<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178684</url>
  </required_header>
  <id_info>
    <org_study_id>SEARCH 014</org_study_id>
    <nct_id>NCT01178684</nct_id>
  </id_info>
  <brief_title>Epidermal Nerve Fiber Density, Fat and Mitochondrial Parameters in Thai HIV+ Patients on d4T and HIV- Patients</brief_title>
  <official_title>Study of Epidermal Nerve Fiber Density, Subcutaneous Fat, and Mitochondrial Parameters in Thai HIV-positive Patients on Long-term Stavudine Treatment and in Thai HIV-negative Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South East Asia Research Collaboration with Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>South East Asia Research Collaboration with Hawaii</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide the range of Epidermal Nerve Fiber Density (ENFD) typically seen in&#xD;
      Thai individuals. ENFD values from Thai HIV-negative subjects without neuropathy will be used&#xD;
      as appropriate reference norm for Thai HIV-positive subjects. In particular, comparison of&#xD;
      ENFD values from Thai HIV-negative subjects with baseline ENFD values in Thai HIV-positive&#xD;
      subjects prior to highly active antiretroviral therapy (HAART) will allow examination of the&#xD;
      effect of HIV per se on ENFD. ENFD from Thai HIV-positive subjects on long-term d4T&#xD;
      (stavudine) with and without neuropathy will also provide reference ENFD values at the&#xD;
      extremes of the disease process i.e. extent of ENFD decrease in subjects with d4T-induced&#xD;
      symptomatic neuropathy and in subjects completely free of disease despite d4T treatment for&#xD;
      comparison with Thai HIV-positive subjects on short-term d4T in SEARCH 003 study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The range of changes in epidermal nerve fiber density (ENFD), subcutaneous fat, and&#xD;
      mitochondrial function induced by stavudine (d4T)-based therapy is currently not known,&#xD;
      globally or specifically in the Thai population. This study will evaluate ENFD and&#xD;
      subcutaneous fat and peripheral blood mitochondrial parameters in 4 groups of subjects. Group&#xD;
      1 will include Thai HIV-positive subjects on long-term d4T treatment with symptomatic&#xD;
      peripheral neuropathy. Group 2 will include Thai HIV-positive subjects on long-term d4T&#xD;
      treatment without peripheral neuropathy. Group 3 will include HIV-negative subjects without&#xD;
      peripheral neuropathy.Group 4 will include Thai HIV-positive subjects on long-term d4T&#xD;
      treatment with asymptomatic peripheral neuropathy. Information gained from Thai HIV-positive&#xD;
      subjects on long-term d4T treatment with and without neuropathy in this study will provide&#xD;
      range of positive control values for subjects in the SEARCH 003 study and other studies&#xD;
      looking at the influence of antiretroviral agents on peripheral nerve, fat, and mitochondria.&#xD;
      Information gained from Thai HIV-negative subjects without neuropathy can be used as negative&#xD;
      control values for subjects in the SEARCH 003 study and other studies looking at the&#xD;
      influence of HIV or other diseases/pathogens on peripheral nerve, fat, and mitochondria.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
        1. HIV-positive patients who have been on long-term d4T treatment with symptomatic&#xD;
           peripheral neuropathy will have less ENFD, increased lipoatrophy, and altered&#xD;
           mitochondrial function than those on long-term d4T treatment with asymptomatic&#xD;
           peripheral neuropathy and those on long-term d4T treatment without peripheral&#xD;
           neuropathy.&#xD;
&#xD;
        2. HIV-negative patients without peripheral neuropathy will have more ENFD, no lipoatrophy,&#xD;
           and better mitochondrial function than HIV-positive patients.&#xD;
&#xD;
      The SEARCH 003 study will assess the extent of deterioration in ENFD induced by short-term&#xD;
      (from entry to 24 weeks) d4T use and the degree of improvement following discontinuation of&#xD;
      d4T (from week 24 to 72). However the range of changes in ENFD and in other mitochondrial&#xD;
      parameters induced by d4T-based therapy in not known, globally or specifically in the Thai&#xD;
      population.&#xD;
&#xD;
      This is a cross-sectional study that will enroll 25 HIV-positive subjects on long-term d4T&#xD;
      treatment with symptomatic peripheral neuropathy, 25 HIV-positive subjects on long-term d4T&#xD;
      treatment without peripheral neuropathy, 50 HIV-negative subjects without peripheral&#xD;
      neuropathy and 25 HIV-positive subjects on long-term d4T treatment with asymptomatic&#xD;
      peripheral neuropathy for a one-time assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of nerves in the skin</measure>
    <time_frame>Baseline</time_frame>
    <description>To compare differences in ENFD between the 4 groups&#xD;
group 1: HIV-positive subjects on long-term d4T with symptomatic peripheral neuropathy&#xD;
group 2: HIV-positive subjects on long-term d4T without peripheral neuropathy&#xD;
group 3: HIV-negative subjects without peripheral neuropathy&#xD;
group 4: HIV-positive subjects on long-term d4T with asymptomatic peripheral neuropathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Condition of lipoatrophy</measure>
    <time_frame>Baseline</time_frame>
    <description>To compare differences lipoatrophy between the 4 groups&#xD;
group 1: HIV-positive subjects on long-term d4T with symptomatic peripheral neuropathy&#xD;
group 2: HIV-positive subjects on long-term d4T without peripheral neuropathy&#xD;
group 3: HIV-negative subjects without peripheral neuropathy&#xD;
group 4: HIV-positive subjects on long-term d4T with asymptomatic peripheral neuropathy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial parameters</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracellular concentrations of d4T triphosphate</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV DNA in peripheral blood mononuclear cell (PBMC)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">113</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>1: HIV-pos on d4T with neuropathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>2: HIV-pos on d4T without neuropathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>3: HIV-neg without peripheral neuropathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>4 HIV-pos on d4T with asymtomatic neuropathy</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma PBMC Urine CBC&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Seventy five HIV-positive patients on long-term d4T treatment (25 with symptomatic&#xD;
        peripheral neuropathy, 25 without peripheral neuropathy and 25 with asymptomatic peripheral&#xD;
        neuropathy) and 50 HIV-negative subjects without peripheral neuropathy will be recruited&#xD;
        from the Thai Red Cross AIDS Research Centre and the Queen Savang Vadhana Memorial&#xD;
        Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Group 1: HIV-positive subjects on long-term d4T with symptomatic peripheral neuropathy&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented HIV-1 infection&#xD;
&#xD;
          -  Age â‰¥ 18 years old&#xD;
&#xD;
          -  Has Thai national identification card&#xD;
&#xD;
          -  Subject on d4T treatment with symptoms of neuropathy which developed after start of&#xD;
             d4T therapy&#xD;
&#xD;
          -  Evidence of symptomatic persistent symptoms of pain, tingling or numbness of lower&#xD;
             extremities AND bilateral lower extremity neuropathy on exam at entry.&#xD;
&#xD;
          -  Subject understands the study and is able to sign informed consent&#xD;
&#xD;
          -  HIV RNA by PCR &lt; 50 copies/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with concomitant medications (other than d4T) or having conditions (e.g.&#xD;
             compressive neuropathy, diabetes, vitamin B12 deficiency, excessive alcohol intake&#xD;
             meeting substance dependence criteria by DSM-IV, hepatitis C infection) known to cause&#xD;
             neuropathy&#xD;
&#xD;
          -  History of allergy to any anesthetic medications&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        Group 2 subjects will meet the same criteria described above for group 1 subjects, but will&#xD;
        NOT have symptoms OR signs of neuropathy.&#xD;
&#xD;
        Group 3 subjects will meet the same criteria described above for group 1 subjects, but will&#xD;
        NOT have symptoms OR signs of neuropathy and will have documented&#xD;
&#xD;
        Group 4 subjects will meet the same criteria described above for group 1 subject, but will&#xD;
        have evidence of symptomatic persistent symptoms of pain, tingling or numbness of lower&#xD;
        extremities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jintanat Ananworanich, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South East Asia Research Collaboration with Hawaii</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>June 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South East Asia Research Collaboration with Hawaii</investigator_affiliation>
    <investigator_full_name>Assoc.Prof.Jintanat Ananworanich, M.D.</investigator_full_name>
    <investigator_title>Assoc.Prof. Jintanat Ananworanich, MD,PhD</investigator_title>
  </responsible_party>
  <keyword>ENFD</keyword>
  <keyword>epidermal nerve fiber density</keyword>
  <keyword>HIV</keyword>
  <keyword>HIV-infection</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

